No connection

Search Results

ROIV

NEUTRAL
$29.83 Live
Roivant Sciences Ltd. · NASDAQ
Target $35.67 (+19.6%)
$10.01 52W Range $30.33
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 19, 2026
Market cap
$21.35B
P/E
N/A
ROE
-19.1%
Profit margin
N/A
Debt/Equity
0.02
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
ROIV presents a stark divergence between deterministic financial health and market sentiment. The Piotroski F-Score of 1/9 indicates severe fundamental weakness, compounded by an absurd Price/Sales ratio of 1604.01 and heavy insider selling totaling $175.18M. However, the company maintains an extraordinary liquidity position with a Current Ratio of 30.66 and negligible debt (Debt/Equity 0.02), suggesting it is a well-funded biotech 'cash shell' betting on its pipeline. While analysts maintain a 'strong_buy' rating with a target of $35.67, the fundamental data is overwhelmingly bearish.

Key Strengths

Exceptional liquidity with a Current Ratio of 30.66
Negligible leverage with a Debt/Equity ratio of 0.02
Strong analyst consensus (Strong Buy) with a positive price target
Significant 1-year price appreciation (+193.9%)
Consistent ability to beat EPS estimates in recent quarters

Key Risks

Critical fundamental weakness indicated by a Piotroski F-Score of 1/9
Extreme valuation disconnect with a Price/Sales ratio of 1604.01
Severe revenue contraction (-77.80% YoY)
Aggressive insider selling ($175.18M in the last 6 months)
Lack of operational profitability with an operating margin of -16965.28%

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
26
Weak
Value
10
Future
60
Past
40
Health
20
Dividend
0
AI Verdict
Speculative High-Risk
Key drivers: Extreme liquidity vs. Zero profitability, Insider dumping vs. Analyst optimism, Pipeline-driven valuation
Confidence
90%
Value
10/100

No Graham Number available due to lack of earnings; valuation is purely speculative.

Positives
No standout positives identified.
Watchpoints
  • P/S ratio of 1604.01 is unsustainable
  • P/B of 4.96 is high for a non-earning entity
Future
60/100

Future value is tied to clinical success rather than current financial growth.

Positives
  • Analyst target price of $35.67 suggests 19% upside
  • Strong recent price momentum
Watchpoints
  • Revenue growth is crashing (-77.8%)
Past
40/100

Price performance has decoupled from financial fundamentals.

Positives
  • Massive 5-year return of +203.5%
Watchpoints
  • Consistent history of negative earnings
Health
20/100

High liquidity prevents bankruptcy risk, but operational health is failing.

Positives
  • Very low debt
  • Massive cash reserves (implied by Current Ratio)
Watchpoints
  • Piotroski F-Score of 1/9 is critically low
Dividend
0/100

Typical for biotech growth/speculative stage.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$29.83
Analyst Target
$35.67
Upside/Downside
+19.6%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ROIV and closest competitors.

Updated 2026-04-17
ROI
Roivant Sciences Ltd.
Primary
5Y
+203.5%
3Y
+236.3%
1Y
+193.9%
6M
+72.8%
1M
+7.3%
1W
+5.7%
HUM
Humana Inc.
Peer
5Y
-54.8%
3Y
-63.9%
1Y
-31.8%
6M
-27.3%
1M
-4.6%
1W
+2.6%
BNT
BioNTech SE
Peer
5Y
-20.9%
3Y
-28.6%
1Y
-2.4%
6M
-9.9%
1M
-17.3%
1W
+2.4%
MRN
Moderna, Inc.
Peer
5Y
-61.7%
3Y
-66.9%
1Y
+79.2%
6M
+96.7%
1M
-3.9%
1W
-1.1%
EXA
Exact Sciences Corp
Peer
5Y
-16.4%
3Y
+58.3%
1Y
+122.8%
6M
+95.9%
1M
+1.4%
1W
+1.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-25.74
PEG Ratio
N/A
P/B Ratio
4.96
P/S Ratio
1604.01
EV/Revenue
1324.82
EV/EBITDA
-13.95
Market Cap
$21.35B

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -16965.3%
Gross Margin N/A
ROE -19.14%
ROA -14.47%

Growth

Revenue and earnings growth rates

Revenue Growth -77.8%
Earnings Growth N/A
Q/Q Revenue Growth -77.83%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.02
Low debt
Current Ratio
30.66
Strong
Quick Ratio
29.81
Excellent
Cash/Share
$6.33

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
65.0%
Op. Margin
-16966.1%
Net Margin
-13301.2%
Total Assets
$5.2B
Liabilities
$0.3B
Equity
$4.3B
Debt/Equity
0.06x
Operating CF
$-0.2B
Free Cash Flow
$-0.2B
FCF Yield
97%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-28
$N/A
2026-02-06
$-0.24
+23.0% surprise
2025-11-10
$-0.28
+9.3% surprise
2025-08-11
$-0.25
-8.7% surprise

Healthcare Sector Comparison

Comparing ROIV against 447 companies in the Healthcare sector (26 bullish, 140 neutral, 281 bearish)
Return on Equity (ROE)
-19.14%
This Stock
vs
-97.42%
Sector Avg
-80.3% (Below Avg)
Debt to Equity
0.02
This Stock
vs
3.06
Sector Avg
-99.3% (Less Debt)
Revenue Growth
-77.8%
This Stock
vs
147.85%
Sector Avg
-152.6% (Slower)
Current Ratio
30.66
This Stock
vs
4.68
Sector Avg
+555.8% (Stronger)

Similar Companies

Peer comparison within the same industry

ROIV Roivant Sciences Ltd.
NEUTRAL
Mkt Cap
$21.3B
P/E
-
ROE
-19.1%
Price
$29.83
HUM Humana Inc.
BEARISH
Mkt Cap
$21.4B
P/E
18.1
ROE
7.0%
Price
$177.86
 Compare with ROIV
BNTX BioNTech SE
BEARISH
Mkt Cap
$22.3B
P/E
-
ROE
-5.9%
Price
$88.88
 Compare with ROIV
MRNA Moderna, Inc.
BEARISH
Mkt Cap
$20.1B
P/E
-
ROE
-28.9%
Price
$50.8
 Compare with ROIV
EXAS Exact Sciences Corp
BEARISH
Mkt Cap
$20.0B
P/E
-
ROE
-8.7%
Price
$104.91
 Compare with ROIV

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

HUMES JENNIFER
Officer
Sell
2026-04-08
13,538 shares · $384,073
SUKHATME MAYUKH
President
Stock Award
2026-03-30
58,391 shares
GLINE MATTHEW
Chief Executive Officer
Stock Award
2026-03-30
97,319 shares
FITZGERALD MEGHAN
Director
Sell
2026-03-26
70,000 shares · $1,921,500
FITZGERALD MEGHAN
Director
Option Exercise
2026-03-26
70,000 shares · $616,000
VENKER ERIC
President
Sell
2026-03-17
200,000 shares · $5,648,000
VENKER ERIC
President
Option Exercise
2026-03-17
200,000 shares · $770,000
EPPERLY MELISSA B
Director
Sell
2026-03-16
41,861 shares · $1,200,573
TORTI FRANK M
Officer
Sell
2026-02-23
3,000,000 shares · $82,039,460
TORTI FRANK M
Officer
Option Exercise
2026-02-23
3,000,000 shares · $11,550,000
MANCHESTER KEITH S
Director
Sell
2026-02-13
1,225,784 shares · $32,658,518
VENKER ERIC
Officer
Sell
2026-02-13
200,000 shares · $5,298,000
VENKER ERIC
Officer
Option Exercise
2026-02-13
200,000 shares · $770,000
GOLD DANIEL ALLEN
Director
Sell
2026-02-13
1,225,784 shares · $32,658,518
SUKHATME MAYUKH
President
Sell
2026-02-09
339,441 shares · $8,985,003
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-02

ROIV filed an 8-K on April 2, 2026, likely to announce its first-quarter financial results.

8-K/A
8-K/A
2026-03-23

ROIV filed an amendment to a previously submitted Current Report on Form 8-K.

8-K
8-K
2026-03-03
8-K
8-K
2026-03-03
10-Q
10-Q
2026-02-06

ROIV filed its 10-Q on February 6, 2026. While specific financial highlights were not provided in the excerpt, the filing includes a dedicated section for risk factors under Item 1A.

8-K
8-K
2026-02-06

ROIV filed a Form 8-K on February 6, 2026, likely to announce its financial results for the preceding period.

8-K
8-K
2025-12-11
10-Q
10-Q
2025-11-10

ROIV filed its 10-Q on November 10, 2025. While specific financial highlights were not provided in the excerpt, the filing includes a dedicated section for risk factors under Item 1A.

8-K
8-K
2025-11-10
8-K
8-K
2025-09-17
8-K
8-K
2025-09-11
8-K
8-K
2025-09-03
8-K
8-K
2025-08-11
10-Q
10-Q
2025-08-11
DEF 14A
DEF 14A
2025-07-29
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
12 analysts
Piper Sandler
2026-04-16
Maintains
Overweight Overweight
HC Wainwright & Co.
2026-03-04
Maintains
Buy Buy
Citigroup
2026-02-10
Maintains
Buy Buy
HC Wainwright & Co.
2026-02-10
Maintains
Buy Buy
Guggenheim
2026-02-09
Maintains
Buy Buy
Leerink Partners
2025-12-15
Maintains
Outperform Outperform
Goldman Sachs
2025-12-15
Maintains
Buy Buy
HC Wainwright & Co.
2025-12-12
Maintains
Buy Buy
Citigroup
2025-11-11
Maintains
Buy Buy
Citigroup
2025-10-29
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning ROIV from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile